Opeyemi Tayo-Balogun

Opeyemi Tayo-Balogun currently serves as Executive Director at Disc Medicine, a position held since April 2025. Prior experience includes roles as Senior Director and Director at FibroGen, Inc. from April 2021 to June 2025, and various leadership positions in external manufacturing at Nektar Therapeutics from November 2018 to April 2021. Opeyemi started the career at Bayer as a Scientist, focusing on product development and purification processes from February 2016 to November 2018, and began in the pharmaceutical industry at Eli Lilly and Company from 2007 to January 2016, optimizing development processes for antibodies. The career commenced as a Research Biologist at Merck between 2004 and 2006, supporting chemical synthesis and conducting various assays. Opeyemi holds a Master's Degree in Biotechnology and a Bachelor's Degree in Biology from Kean University.